Skip to main content
SteadySharesSteadySharesSteadyStShares
The market
MarketsDiscover
Follow the money
Super InvestorsPolitician TradesCrypto Desk
Yours
My WealthNews
Settings Sign in to save your work
Closed
SteadySharesMarketsDiscoverSuper InvestorsMy WealthPoliticiansCryptoNews
DiscoverCURX
HealthcareNCMUSD

Curanex Pharmaceuticals Inc

$00123456789.0012345678900123456789-6.0%
52w low (est.) $0.15$0.24 52w high (est.)
Market data · updated 1h ago
Market data
Market cap
USD5.33M
52w range
USD0.19 - USD9.18
Beta
1.00
Sector
Healthcare
Data quality
71/100
Valuation
DCF fair value
USD0.08
Margin of safety
-57.4%
Quality & efficiency
Moat score
5/100
Return on equity
-85.2%
Debt / equity
1.56
Run the 10-point checklist before you buy How these numbers are made

About Curanex Pharmaceuticals Inc

Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients suffering from inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The company was formerly known as Fordman Pharma Inc. and changed its name to Curanex Pharmaceuticals Inc in November 2023. Curanex Pharmaceuticals Inc was founded in 1996 and is headquartered in Jericho, New York.

Valuation

ValueGrowthProfitHealthIncome13QUALITY
Overall Rating
7
Sell
Sell

Derived from filed metrics · Moderate confidence (71% of the inputs available)

Moat Score5
DCF Intrinsic Value
USD0.08-57.4% downside

Moat, DCF and rating computed by our valuation engine (ported from the original Python model).

Fundamentals

Market Cap
USD5.33M
P/E Ratio
N/A
Dividend Yield
0.00%
Revenue Growth
0.0%
Profit Margin
0.0%
ROE
-85.2%
Debt / Equity
1.56
Beta
1.00
Beaten Down
vs Healthcare sector:Moat 5 vs 7Yield 0.00% vs 0.3%

Statistics

Similar Stocks · Healthcare

LLY73
$920.00+0.7%
AZN.L72
£105.20+0.6%
UNH71
$492.10+1.6%
JNJ70
$146.20-0.2%

Latest News · CURX